Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

NCT07040592 on ClinicalTrials.gov · last registry update 2026-03-24

A small phase 2 — 30 participants, against a typical 110. Due to report 30 June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Proportion of participants who complete enrollment and duration of sessions. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Yale University
Sponsor type: Other
Enrollment: 30
Started: 2026-01-15
Primary completion: 2027-06-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion of participants who complete enrollment and duration of sessions

Conditions studied

Alcohol Use Disorder (AUD) · HIV

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.